Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

A Phase 2 Trial Investigating Epcoritamab in Patients with Previously Treated Waldenstrom Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (WM-NET3)

Gottfried von Keudell, Emma K Logan, Robert A. Redd, Shayna R Sarosiek, Andrew R. Branagan, Larry D Anderson, Jr., Christopher Dittus, Steven P. Treon, Jorge J. Castillo

Blood (2024) 144 (Supplement 1): 6294.

https://doi.org/10.1182/blood-2024-206415

Published: 2024

Journal Articles

Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia

Jorge J. Castillo, Shayna R Sarosiek, Andrew R. Branagan, Gottfried von Keudell, Catherine A. Flynn, Andres Ramirez-Gamero, Nina S Budano, Alexandra N. Eurell, Kirsten Meid, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nickolas Tsakmaklis, Christopher J Patterson, Zachary R Hunter, Steven P. Treon

Blood (2024) 144 (Supplement 1): 1647.

https://doi.org/10.1182/blood-2024-198376

Published: 2024

Journal Articles

Biological Correlatives of Efficacy and Toxicity of BCMA Targeting CAR T Cell Therapy in a Real-World Setting

Blood (2024) 144 (Supplement 1): 7126.

https://doi.org/10.1182/blood-2024-194895

Published: 2024

Journal Articles

Previous HDM/ASCT Adversely Impacts PFS with BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma

Joshua Gustine, Diana Cirstea, Andrew R. Branagan, Andrew J. Yee, Marcela Maus, Matthew J. Frigault, Noopur Raje

Blood (2024) 144 (Supplement 1): 79.

https://doi.org/10.1182/blood-2024-212135

Published: 2024

Journal Articles

Development and Evaluation of a Multiplex Digital PCR Assay for Detecting CXCR4 S338X Mutations in Waldenstrom's Macroglobulinemia

Nickolas Tsakmaklis, Zachary R Hunter, Amanda Kofides, Xia Liu, Shirong Liu, Hao Sun, Abigail Peachey, Maria Luisa Guerrera, Christopher J Patterson, Joshua Gustine, Andrew R. Branagan, Shayna R Sarosiek, Jorge J. Castillo, Steven P. Treon

Blood (2024) 144 (Supplement 1): 6194.

https://doi.org/10.1182/blood-2024-211703

Published: 2024

Journal Articles

A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis

Jorge J. Castillo, Shayna R Sarosiek, Andrew R. Branagan, Gottfried von Keudell, Catherine A. Flynn, Nina S Budano, Alexandra N. Eurell, Kirsten Meid, Andres Ramirez-Gamero, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nickolas Tsakmaklis, Christopher J Patterson, Zachary R Hunter, Steven P. Treon

Blood (2024) 144 (Supplement 1): 3011.

https://doi.org/10.1182/blood-2024-198297

Published: 2024

Journal Articles

Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström's Macroglobulinemia and Represent Novel Therapeutic Targets.

Blood (2024) 144 (Supplement 1): 2972.

https://doi.org/10.1182/blood-2024-211759

Published: 2024

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential Does Not Impact Overall Survival in Multiple Myeloma

Farah Rexha, Joshua Gustine, Ryan Han, Rie Nakamoto-Matsubara, Cristina Panaroni, Rajib Shome, Valentina Nardi, Andrew R. Branagan, Diana Cirstea, Andrew J. Yee, Noopur Raje

Blood (2024) 144 (Supplement 1): 3339.

https://doi.org/10.1182/blood-2024-211622

Published: 2024

Journal Articles

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

Jorge J. Castillo, Andrew R. Branagan, David Sermer, Catherine A. Flynn, Kirsten Meid, Megan Little, Katherine Stockman, Timothy White, Alexa Canning, Maria L. Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nicholas Tsakmaklis, Christopher J. Patterson, Zachary R. Hunter, Steven P. Treon, Shayna Sarosiek

Blood (2024) 143 (7): 582–591.

https://doi.org/10.1182/blood.2023022420

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Elizabeth K. O'Donnell, Clifton C. Mo, Andrew J. Yee, Omar Nadeem, Andrew R. Branagan, Jacob Laubach, Jacalyn Rosenblatt, Nora Horick, Paul G. Richardson, Noopur Raje, Diana Cirstea

Blood (2023) 142 (Supplement 1): 4671.

https://doi.org/10.1182/blood-2023-181019

Published: 2023

Journal Articles

Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth

Maria Luisa Guerrera, Zachary R Hunter, Kris Richardson, Nickolas Tsakmaklis, Amanda Kofides, Shirong Liu, Christopher J Patterson, Eugenio Morelli, Jorge J. Castillo, Shayna R Sarosiek, Catherine A. Flynn, Kirsten Meid, Andrew R. Branagan, Ruben D. Carrasco, Kenneth C. Anderson, Nikhil C Munshi, Steven P Treon, Xia Liu

Blood (2023) 142 (Supplement 1): 3303.

https://doi.org/10.1182/blood-2023-190880

Published: 2023

Journal Articles

Prospective Study of Acalabrutinib with Rituximab in Patients with Symptomatic Anti-MAG Mediated IgM Peripheral Neuropathy

Shayna R Sarosiek, Andrew R. Branagan, Christopher Doughty, Catherine A. Flynn, Megan Little, Katherine Stockman, Timothy P. White, Kirsten Meid, Steven P Treon, Jorge J. Castillo

Blood (2023) 142 (Supplement 1): 213.

https://doi.org/10.1182/blood-2023-185113

Published: 2023

Journal Articles

Quantitative MYD88 L265P Analysis Represents a Powerful Tool for Assessing Disease Response and Evaluating Clinical Trial Performance in Waldenstrom's Macroglobulinemia

Nickolas Tsakmaklis, Zachary R Hunter, Xia Liu, Amanda Kofides, Shirong Liu, Alexa G Canning, Kris Richardson, Maria Luisa Guerrera, Christopher J Patterson, Kirsten Meid, Timothy P. White, Megan Little, Katherine Stockman, Joshua Gustine, Catherine A. Flynn, Andrew R. Branagan, Shayna R Sarosiek, Jorge J. Castillo, Steven P Treon

Blood (2023) 142 (Supplement 1): 211.

https://doi.org/10.1182/blood-2023-190520

Published: 2023

Journal Articles

Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia

Jorge J. Castillo, Shayna R Sarosiek, Andrew R. Branagan, Catherine A. Flynn, Megan Little, Katherine Stockman, Timothy P. White, Alexandra N. Eurell, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nickolas Tsakmaklis, Kirsten Meid, Christopher J Patterson, Zachary R Hunter, Steven P Treon

Blood (2023) 142 (Supplement 1): 1661.

https://doi.org/10.1182/blood-2023-174375

Published: 2023

Journal Articles

Use of Cilta-Cel CAR T Cells Following Previous Use of a BCMA-Directed CAR T-Cell Product in Heavily Treated Patients with Relapsed/Refractory Multiple Myeloma: A Single Institution Case Series

Narsis Attar, Diana Cirstea, Andrew R. Branagan, Andrew J. Yee, Matthew J. Frigault, Noopur Raje

Blood (2023) 142 (Supplement 1): 6924.

https://doi.org/10.1182/blood-2023-182212

Published: 2023

Journal Articles

Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Blood (2022) 140 (Supplement 1): 10094–10096.

https://doi.org/10.1182/blood-2022-167899

Published: 2022

Journal Articles

The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

Blood (2022) 140 (Supplement 1): 1549–1550.

https://doi.org/10.1182/blood-2022-169863

Published: 2022

Journal Articles

Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

Jorge J. Castillo, Shayna Sarosiek, Andrew R. Branagan, David J. Sermer, Catherine A. Flynn, Carly Leventoff, Megan Little, Timothy P White, Kirsten Meid, Alexa Canning, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J Patterson, Zachary R Hunter, Steven P Treon

Blood (2022) 140 (Supplement 1): 564–565.

https://doi.org/10.1182/blood-2022-155610

Published: 2022

Journal Articles

Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom's Macroglobulinemia

Blood (2022) 140 (Supplement 1): 3541–3542.

https://doi.org/10.1182/blood-2022-170254

Published: 2022

Journal Articles

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Elizabeth K. O'Donnell, Clifton C Mo, Omar Nadeem, Andrew J. Yee, Andrew R. Branagan, Jacob Laubach, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Cynthia C. Harrington, Emerentia Agyemang, Jacalyn Rosenblatt, Nora K. Horick, Paul G. Richardson, Noopur Raje

Blood (2022) 140 (Supplement 1): 7282–7283.

https://doi.org/10.1182/blood-2022-156328

Published: 2022

NARROW

A Phase 2 Trial Investigating Epcoritamab in Patients with Previously Treated Waldenstrom Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (WM-NET3)

Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia

Biological Correlatives of Efficacy and Toxicity of BCMA Targeting CAR T Cell Therapy in a Real-World Setting

Previous HDM/ASCT Adversely Impacts PFS with BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma

Development and Evaluation of a Multiplex Digital PCR Assay for Detecting CXCR4 S338X Mutations in Waldenstrom's Macroglobulinemia

A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis

Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström's Macroglobulinemia and Represent Novel Therapeutic Targets.

Clonal Hematopoiesis of Indeterminate Potential Does Not Impact Overall Survival in Multiple Myeloma

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth

Prospective Study of Acalabrutinib with Rituximab in Patients with Symptomatic Anti-MAG Mediated IgM Peripheral Neuropathy

Quantitative MYD88 L265P Analysis Represents a Powerful Tool for Assessing Disease Response and Evaluating Clinical Trial Performance in Waldenstrom's Macroglobulinemia

Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia

Use of Cilta-Cel CAR T Cells Following Previous Use of a BCMA-Directed CAR T-Cell Product in Heavily Treated Patients with Relapsed/Refractory Multiple Myeloma: A Single Institution Case Series

Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom's Macroglobulinemia

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only